196 related articles for article (PubMed ID: 16841630)
1. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF
J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630
[TBL] [Abstract][Full Text] [Related]
2. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.
Sanger TM; Grundy SL; Gibson PJ; Namjoshi MA; Greaney MG; Tohen MF
J Clin Psychiatry; 2001 Apr; 62(4):273-81. PubMed ID: 11379842
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico.
Tamayo JM; Sutton VK; Mattei MA; Diaz B; Jamal HH; Vieta E; Zarate CA; Fumero I; Tohen M
J Clin Psychopharmacol; 2009 Aug; 29(4):358-61. PubMed ID: 19593175
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study.
Marangell LB; Johnson CR; Kertz B; Zboyan HA; Martinez JM
J Clin Psychiatry; 2002 May; 63(5):391-5. PubMed ID: 12019662
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.
Macfadden W; Adler CM; Turkoz I; Haskins JT; Turner N; Alphs L
BMC Psychiatry; 2011 Oct; 11():171. PubMed ID: 22034906
[TBL] [Abstract][Full Text] [Related]
6. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
[TBL] [Abstract][Full Text] [Related]
7. A novel augmentation strategy for treating resistant major depression.
Shelton RC; Tollefson GD; Tohen M; Stahl S; Gannon KS; Jacobs TG; Buras WR; Bymaster FP; Zhang W; Spencer KA; Feldman PD; Meltzer HY
Am J Psychiatry; 2001 Jan; 158(1):131-4. PubMed ID: 11136647
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.
Schmidt ME; Fava M; Robinson JM; Judge R
J Clin Psychiatry; 2000 Nov; 61(11):851-7. PubMed ID: 11105738
[TBL] [Abstract][Full Text] [Related]
9. Influence of fluoxetine on olanzapine pharmacokinetics.
Gossen D; de Suray JM; Vandenhende F; Onkelinx C; Gangji D
AAPS PharmSci; 2002; 4(2):E11. PubMed ID: 12102620
[TBL] [Abstract][Full Text] [Related]
10. A Canadian naturalistic study of a community-based cohort treated for bipolar disorder.
Sagman D; Lee B; Chandresena R; Jones B; Brunner E
BMC Psychiatry; 2010 Mar; 10():24. PubMed ID: 20302634
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder.
Dinan TG
J Clin Psychiatry; 2001; 62 Suppl 22():48-52. PubMed ID: 11599649
[TBL] [Abstract][Full Text] [Related]
12. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.
Calabrese JR; Bowden CL; Sachs GS; Ascher JA; Monaghan E; Rudd GD
J Clin Psychiatry; 1999 Feb; 60(2):79-88. PubMed ID: 10084633
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
Poyurovsky M; Pashinian A; Gil-Ad I; Maayan R; Schneidman M; Fuchs C; Weizman A
Am J Psychiatry; 2002 Jun; 159(6):1058-60. PubMed ID: 12042201
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.
Tohen M; Jacobs TG; Grundy SL; McElroy SL; Banov MC; Janicak PG; Sanger T; Risser R; Zhang F; Toma V; Francis J; Tollefson GD; Breier A
Arch Gen Psychiatry; 2000 Sep; 57(9):841-9. PubMed ID: 10986547
[TBL] [Abstract][Full Text] [Related]
15. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression.
Bennie EH; Mullin JM; Martindale JJ
J Clin Psychiatry; 1995 Jun; 56(6):229-37. PubMed ID: 7775364
[TBL] [Abstract][Full Text] [Related]
16. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression.
McGrath PJ; Stewart JW; Petkova E; Quitkin FM; Amsterdam JD; Fawcett J; Reimherr FW; Rosenbaum JF; Beasley CM
J Clin Psychiatry; 2000 Jul; 61(7):518-24. PubMed ID: 10937611
[TBL] [Abstract][Full Text] [Related]
17. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study.
Robinson RG; Schultz SK; Castillo C; Kopel T; Kosier JT; Newman RM; Curdue K; Petracca G; Starkstein SE
Am J Psychiatry; 2000 Mar; 157(3):351-9. PubMed ID: 10698809
[TBL] [Abstract][Full Text] [Related]
18. The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania.
Baker RW; Goldberg JF; Tohen M; Milton DR; Stauffer VL; Schuh LM
Bipolar Disord; 2002 Feb; 4(1):43-9. PubMed ID: 12047494
[TBL] [Abstract][Full Text] [Related]
19. Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice.
Kulkarni J; Filia S; Berk L; Filia K; Dodd S; de Castella A; Brnabic AJ; Lowry AJ; Kelin K; Montgomery W; Fitzgerald PB; Berk M
BMC Psychiatry; 2012 Dec; 12():228. PubMed ID: 23244301
[TBL] [Abstract][Full Text] [Related]
20. The pharmacotherapy of depressive illness in adolescents: an open-label comparison of fluoxetine with imipramine-treated historical controls.
Strober M; DeAntonio M; Schmidt-Lackner S; Pataki C; Freeman R; Rigali J; Rao U
J Clin Psychiatry; 1999 Mar; 60(3):164-9. PubMed ID: 10192591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
